Vishwa Shah
Chief Quality OfficerViatris
PharmaceuticalsView Profile →Senior Vice President, Clinical Development Unit Head, Hematology · Regeneron Pharmaceuticals
L. Andres Sirulnik is senior vice president and clinical development unit head for hematology at Regeneron Pharmaceuticals. He joined in 2020 after serving as chief medical officer at Merus and leading immuno-oncology clinical strategy at Novartis.
Last reviewed: Oct 21, 2026
Senior Vice President, Clinical Development Unit Head, Hematology Regeneron Pharmaceuticals
Last Reviewed: October 21, 2026
L. Andres Sirulnik is senior vice president and clinical development unit head for hematology at Regeneron Pharmaceuticals. He joined in 2020 after serving as chief medical officer at Merus and leading immuno-oncology clinical strategy at Novartis.
Sirulnik trained in medicine in Argentina and completed doctoral research in the United Kingdom. His subsequent training included postdoctoral work at Columbia University, a residency at North Shore–Long Island Jewish Health System and a hematology/oncology fellowship at Mount Sinai. He formerly practiced at Dana-Farber Cancer Institute and Brigham and Women’s Hospital.
He spent a decade at Novartis, advancing to oversee clinical strategy for its immuno-oncology portfolio. He later served as chief medical officer of Merus before joining Regeneron in 2020.
He now leads strategic program direction and clinical sciences for early- and late-stage oncologic hematology and late-stage non-oncology hematology. The role combines his clinical and research background with development leadership across both malignant and nonmalignant blood disorders.
Sirulnik earned a PhD in medicine and molecular biology from King’s College, University of Cambridge, and an MD from the University of Buenos Aires.